N=1 After 40

Current experiment · August 2026

SLU-PP-915

An oral experiment started at 10 mg/day after waking on August 20 and has since been titrated to 20 mg/day. The primary question is whether it produces repeatable exercise energy; weight loss and body composition are secondary outcomes. Personal experiment record, not medical advice, prescribing, sourcing guidance, or an instruction to copy.

Primary question: Does 20 mg of oral SLU-PP-915 after waking produce a repeatable improvement in exercise energy, cardio capacity, or training output, with weight loss as a secondary result?

Research Summary

What it is

SLU-PP-915 is a synthetic small-molecule agonist of all three estrogen-related receptors: ERRα, ERRβ, and ERRγ. These orphan nuclear receptors regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and cellular energy use. Despite the name, SLU-PP-915 is not estrogen and it is not a peptide.

Why it is different from SLU-PP-332

SLU-PP-915 is not simply an oral formulation of SLU-PP-332. It is a chemically distinct thiophene-based molecule containing a boronic-acid group. The medicinal-chemistry program retained activity across all three ERRs while improving metabolic stability, and later mouse work demonstrated oral systemic exposure and exercise-mimetic activity.

The gene-program rationale

Early cell and mouse experiments found increased expression of ERR target genes including PGC-1α, LDHA, DDIT4, and PDK4. Those genes sit within pathways related to mitochondrial adaptation, fuel use, and the acute response to aerobic exercise. DDIT4 became a central marker in the later performance study because its induction tracked with running time and distance in mice.

The mouse exercise result

In an acute experiment, 20 mg/kg of SLU-PP-915 given by intraperitoneal injection one hour before running increased mouse treadmill time and distance to exhaustion, with performance similar to 50 mg/kg of SLU-PP-332. In seven-day experiments, oral SLU-PP-915 given twice daily increased DDIT4 expression, mitochondrial gene expression, mitochondrial DNA content, and running performance. Exercise and SLU-PP-915 together produced a larger molecular response than either alone.

What the study does not establish

The exercise experiments were conducted in mice, not people. They do not establish a human performance dose, pharmacokinetic profile, safety range, or expected subjective effect. My current 20 mg/day exposure is therefore a personal record rather than a translation of a clinically validated protocol.

The weight-loss hypothesis is secondary

The SLU-PP-915 performance paper did not test human weight loss and was centered on aerobic capacity and skeletal-muscle signaling. The body-composition rationale comes indirectly from ERR control of fatty-acid metabolism and from mouse studies of SLU-PP-332 that reported higher energy expenditure, greater fatty-acid oxidation, and less fat-mass accumulation. That makes weight loss worth observing here, but not the primary claim being tested.

Sources

The Experiment

Start and protocol

I started SLU-PP-915 on August 20, 2026 with one 10 mg oral pill just after waking each day, then increased to 20 mg after waking to pursue greater benefit. The DoseRunway ledger records three consecutive 10 mg administrations through its August 22 export. The public source is listed as Research Compound. This records my use; it is not a suggested dose or protocol.

Primary outcome: exercise energy

The main test is whether exercise feels more sustainable and whether that translates into repeatable output. I am looking for stronger cardio capacity, less fade across a session, better repeated efforts, or more usable energy during lifting—not merely an acute sensation after taking the pill.

Secondary outcome: weight loss

I will also watch for a meaningful change in weight or visible body composition. That result is secondary because Retatrutide and SANA are active at the same time, making a small isolated SLU-PP-915 fat-loss effect harder to identify than a repeatable change during exercise.

What I will watch

For training, the useful signals are session energy, cardio pace at a comparable heart rate or effort, cardiac drift, repeated-interval performance, lifting output, rest needs, and next-day recovery. For body composition, the useful context is the seven-day weight trend, waist, and standardized visual comparisons.

Decision rule

SLU-PP-915 earns a continued place only if exercise energy or output improves in a way that repeats across sessions. Weight loss can strengthen the result, but a one-off stimulant feeling or ordinary day-to-day variation will not count as a useful signal.

Status

The experiment is active. The first ledgered doses establish the exposure, but it is too early to record an outcome.